Afrezza® can help you with blood sugar control without the need for mealtime injections. Before you take your first dose, make sure you understand how Afrezza® works and how to use the inhaler. It is also important to check your blood sugar frequently to track how Afrezza® is working for you. Discuss your results with your healthcare provider so you can adjust your dose if needed.
Afrezza® is available in 4-, 8- and 12-unit color-coded cartridges. If needed, you can mix and match cartridges to take your prescribed dose.
For example, two 12-unit cartridges provide a dose of 24 units of Afrezza®.
Like all insulin therapy, monitor the effect Afrezza® has on you, and reach out to your doctor if you feel like you need to change your dosing.
In clinical trials, most patients received 12-24 Afrezza® insulin units per meal.
Because Afrezza® is inhaled, and is in powered form, one unit of Afrezza® may work differently than one unit of injectable, liquid insulin.
Based on clinical trials, it may take 1.5x the amount of Afrezza® to achieve the same blood sugar control as injected insulin.
This table can help provide a starting point for mealtime dose conversion, but you and your healthcare provider should decide on the appropriate starting dose for your specific needs.
Before you take your first dose, make sure to learn proper inhalation technique and how Afrezza® works. You can download our step-by-step guide, or watch the How to Use Afrezza® video.
*For the 4-unit and 12-unit cartridges, respectively
New cartridges have the cup positioned forward near the point. Used cartridges will have the cup positioned in the center.
Download our Storage & Handling Guide to learn how to properly store the inhaler and cartridges.
Use a calendar or the chart on the back of the inhaler box to help you remember to switch out your inhaler after 15 days of use.
Afrezza® can cause serious side effects, including: Sudden lung problems (bronchospasms). Do not use Afrezza® if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD). Before starting Afrezza®, your healthcare provider will give you a breathing test to check how your lungs are working.
What is the most important information I should know about Afrezza®?
Afrezza® can cause serious side effects, including:
Sudden lung problems (bronchospasms). Do not use Afrezza® if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD). Before starting Afrezza®, your healthcare provider will give you a breathing test to check how your lungs are working.
Do not use Afrezza® if you:
Before using Afrezza®, tell your healthcare provider about all your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins or herbal supplements.
Before you start using Afrezza®, talk to your healthcare provider about low blood sugar and how to manage it.
While using Afrezza® do not:
Afrezza® may cause serious side effects that can lead to death, including:
See “What is the most important information I should know about Afrezza®?” at the top of this page.
Treatment with TZDs and Afrezza® may need to be changed or stopped by your healthcare provider if you have new or worse heart failure.
Get emergency medical help if you have:
• Trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion.
The most common side effects of Afrezza® include:
These are not all the possible side effects of Afrezza®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088).
Active ingredient: human insulin
Inactive ingredients: fumaryl diketopiperazine, polysorbate 80
General information about the safe and effective use of Afrezza®.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Afrezza® for a condition for which it was not prescribed. Do not give Afrezza® to other people, even if they have the same symptoms that you have. It may harm them.
This Medication Guide summarizes the most important information about Afrezza®. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about Afrezza® that is written for health professionals.
AFREZZA®, MANNKIND, and the Afrezza® and MannKind logos are registered marks, all owned by MannKind Corporation. © MannKind Corporation 2020.
This site is intended for use by U.S. residents only